Aios Medical

Aios Medical is dedicated to accelerating the widespread adoption of consumer biotech products, with the ambitious goal of enabling individuals to live healthier lives, ideally reaching a century or more. Currently, the company is concentrating on addressing excess body weight by facilitating increased access to GLP-1 medications, aiming to combat obesity on a global scale.

To achieve this, Aios Medical is developing ClinicOS, an AI-driven clinical operating system designed to streamline direct-to-patient healthcare services for consumer brands worldwide. The company collaborates with external brand partners while also leveraging its infrastructure to expand its own portfolio of internal consumer healthcare brands. Since launching Fella Health in the US in June 2021, Aios Medical has established a strong presence in the weight loss market, particularly catering to busy men. Today, the company manages multiple brands across the US and UK, including Fella Health and Bolt Pharmacy.

Aios Medical envisions its infrastructure serving 100 million patients globally by 2035, paving the way for the distribution of next-generation biotech products at scale, ultimately contributing to a greater proportion of the population living longer, healthier lives. The company aims to become the world's first trillion-dollar healthcare company.

Since August 2021, Aios Medical has experienced substantial growth, exceeding 1000x. They have over 50,000 customers with high NPS and generate over $100 million in annual revenue. The company has been cash flow positive since June 2023.